Abstract
IMPORTANCE Nirmatrelvir-ritonavir, an efficacious treatment for acute COVID-19, has yielded conflicting evidence regarding its effectiveness in preventing Long COVID among adults. The effectiveness of nirmatrelvir-ritonavir in adolescents in real-world settings is not well understood.
OBJECTIVE To evaluate the effectiveness of nirmatrelvir-ritonavir in adolescents aged 12 to 20 years given within the first five days of acute COVID-19 illness on illness severity during the acute (days 0 to 27) and post-acute phases (days 28 to 179).
DESIGN, SETTING, AND PARTICIPANTS This target trial emulation used the electronic health records (EHR) data from twenty-nine medical institutions participating in the NIH’s RECOVER consortium. We included data collected between April 1, 2022 and December 31, 2023, and included all patients with a SARS-CoV-2 infection who were not hospitalized on the day of entry. Those who were treated with oral nirmatrelvir-ritonavir within 5 days after the positive test (n=2,923) and those who did not received nirmatrelvir-ritonavir within 5 days after the positive test during the acute phase of SARS-CoV-2 infection (control group, n=31,947) were identified.
EXPOSURES Treatment with nirmatrelvir-ritonavir based on prescription records.
MAIN OUTCOMES AND MEASURES We used modified Poisson regression models for binary outcomes to examine the effects of nirmatrelvir-ritonavir on acute phase hospitalization, emergency department (ED) visits, and outpatient visits as well as progression to moderate or severe acute illness among individuals treated with nirmatrelvir-ritonavir compared to control counterparts. Additionally, we assessed the medication’s associations with 16 conditions and symptoms during the acute phase of illness and its subsequent association with specific Long COVID diagnostic code U09.9 during the post-acute phase. We reported the absolute risks and estimated the relative risks (RRs), with adjustments made for demographic variables, clinical characteristics, and healthcare utilization, using propensity score matching.
RESULTS The study cohort included 34,870 adolescents (median [Q1, Q3] age 16.0 [14.0, 18.0]); 46.0% male and 43.2% Non-Hispanic White. Among these patients, 2,923 were treated with nirmatrelvir-ritonavir within 5 days of cohort entry and 31,947 received no treatment. The absolute rates were 0.58% vs. 0.96% for hospitalization, 74.17% vs. 82.66% for outpatient visits, 1.81% vs. 2.28% for ED visits, 3.08% vs. 3.99% for moderate/severe acute illness, and 0.21% vs. 0.20% for long COVID diagnosis in the treatment vs. control group. After propensity score matching, during acute-phase period, compared to the control group, nirmatrelvir-ritonavir was associated with reduced risk of any hospitalization (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29-0.80), outpatient visit (RR 0.86; 95% CI 0.82-0.90), and moderate/severe acute illness (RR 0.69; 95% CI 0.56-0.87). Additionally, nirmatrelvir-ritonavir was associated with reduced risk of 7 of 16 specified conditions in chest pain (RR 0.41; 95% CI 0.26-0.63), fatigue and malaise (RR 0.49; 95% CI 0.32-0.76), generalized pain (RR 0.65; 95% CI 0.45-0.95), headache (RR 0.60; 95% CI 0.44-0.83), mental health (RR 0.56; 95% CI 0.39-0.80), musculoskeletal (RR 0.63, 95% CI 0.43-0.94), and respiratory signs and symptoms (RR 0.61, 95% CI 0.52-0.71). No evidence was found to suggest that the treatment was associated with the risk of long COVID diagnosis U09.9 (RR 0.96, 95% CI 0.40-2.32).
CONCLUSIONS AND RELEVANCE This study found that treatment with nirmatrelvir-ritonavir in adolescents within 5 days of SARS-CoV-2 infection, was associated with reduced risk of acute-phase COVID-19 illness and subsequent healthcare utilization. However, treatment was not associated with a lower risk of Long COVID diagnosis.
Question Does treatment with nirmatrelvir-ritonavir reduce the acute COVID-19 illness severity and the risk of developing Long COVID in adolescents aged 12 to 20 years?
Findings In this target trial emulation study of 34,870 adolescents with SARS-CoV-2 infection who were not hospitalized on the cohort entry day, 2,923 who were treated with nirmatrelvir-ritonavir exhibited lower acute illness severity including reduced risk of 7 of 16 specified conditions and symptoms, as well as reduced risk of acute-phase hospitalization and outpatient visits, compared with 31,947 who received no treatment. The association with reduced risk of Long COVID was not observed in this study.
Meaning In adolescents, nirmatrelvir-ritonavir appears to be effective at reducing the severity of acute COVID illness but was not associated with the risk of developing Long COVID.
Competing Interest Statement
Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. Dr. Horne is a member of the advisory boards of Opsis Health and Lab Me Analytics, a consultant to Pfizer regarding risk scores (funds paid to Intermountain), and an inventor of risk scores licensed by Intermountain to Alluceo and CareCentra. Dr. Horne is site PI of a COVID-19 grant from the Task Force for Global Health, site PI of grants from the Patient-Centered Outcomes Research Institute, a member of the advisory board of Opsis Health, and previously consulted for Pfizer regarding risk scores (funds paid to Intermountain). Dr. Newland received industry funded grant support from Pfizer. Dr. Patel reports funding from the National Institute of Health and Bayer Pharmaceuticals. Dr. Chen reported receiving personal fees from Merck & Co., Inc. and Pfizer Inc. outside the submitted work. The remaining authors have no conflicts of interest to report.
Funding Statement
This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of Pennsylvania gave ethnical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Authorship Statement: Authorship has been determined according to ICMJE recommendations.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos